文献速递乳房整形与再造创面修复

新辅助化疗对假体乳房重建结局的影响

The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes.
PubMed 文献 · Plast Reconstr Surg · 2025-08-26

本研究纳入2017至2022年接受即刻组织扩张器(TE)乳房重建的女性患者2013例,其中1202例(59.7%)接受新辅助化疗(NACT),811例(40.3%)未接受化疗。结果显示NACT组TE丢失率显著高于对照组(9.8% vs 3.9%,P<0.001),多变量回归显示NACT显著增加TE丢失风险(OR 2.39,95%CI 1.47-3.93,P<0.001),但未延迟放疗开始;发生蜂窝织炎者放疗平均延迟17天(95%CI 3.5-31,P=0.014)。

要点

  • NACT显著增加即刻TE乳房重建的TE丢失率(OR 2.39)。
  • NACT未延迟辅助放疗的开始时间。
  • 发生蜂窝织炎者放疗平均延迟17天。

核心结论

  • NACT是TE丢失的显著预测因素,但不延长至放疗开始的时间。
  • NACT组TE丢失率升高可能反映辅助放疗比例更高及NACT与放疗对伤口愈合的不良影响叠加。

研究设计与样本

  • 回顾性队列研究,纳入2017至2022年接受即刻TE乳房重建的女性患者2013例。
  • NACT组1202例(59.7%),未化疗对照组811例(40.3%)。

主要发现

  • NACT组TE丢失率9.8%,对照组3.9%(P<0.001)。
  • 多变量回归显示NACT显著增加TE丢失风险(OR 2.39,95%CI 1.47-3.93,P<0.001),未增加其他并发症包括蜂窝织炎。
  • NACT未延迟放疗开始;发生蜂窝织炎者放疗平均延迟17天(95%CI 3.5-31,P=0.014)。

关键数值与推荐

  • 纳入标准:完成NACT且在乳房切除术后2个月内,或未接受化疗。
  • 排除标准:双侧预防性乳房切除、延迟重建、辅助化疗、新辅助放疗。

临床怎么用

  • 对接受NACT后行即刻TE乳房重建的患者,应警惕TE丢失风险升高。
  • 需关注蜂窝织炎对放疗启动时间的延迟影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy (NACT) is a critical component of breast cancer treatment, yet its impact on tissue expander (TE)-based breast reconstruction remains unclear. The purpose of this study was to examine the impact of NACT on complication rates after immediate TE-based breast reconstruction and on the commencement of adjuvant radiotherapy. METHODS: Female patients who underwent immediate TE-based breast reconstruction between 2017 and 2022 were included. Inclusion criteria consisted of patients who completed NACT within 2 months of mastectomy and those who did not receive chemotherapy. Patients who underwent bilateral prophylactic mastectomy, delayed reconstruction, adjuvant chemotherapy, and neoadjuvant radiation therapy were excluded. RESULTS: A total of 2013 patients were included, of whom 1202 (59.7%) received NACT, and 811 (40.3%) did not receive chemotherapy. The rate of TE loss was significantly higher in the NACT cohort than in the control cohort (9.8% versus 3.9%; P < 0.001). Multivariable regression models showed that NACT significantly increases the rate of TE loss (OR, 2.39; 95% CI, 1.47 to 3.93; P < 0.001) but no other complications, including cellulitis. NACT did not delay the commencement to radiation therapy. However, patients who developed cellulitis started radiation therapy on average 17 days later than those who did not (95% CI, 3.5 to 31; P = 0.014). CONCLUSIONS: NACT is a significant predictor of TE loss but does not prolong the commencement to radiotherapy. The increased rate of TE loss among the NACT group may reflect a higher rate of adjuvant radiation treatment and the combination of the deleterious effects of NACT and radiation therapy on wound healing.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Kim M, Barnett JM, Olla DR, et al. The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes. Plast Reconstr Surg. 2025. PMID: 40875534. doi:10.1097/PRS.0000000000012415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。